Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis

An approach to a personalized medicine

Elisa Gremese, Antonio Carletto, Melissa Padovan, Fabiola Atzeni, Bernd Raffeiner, Anna Rita Giardina, Ennio Giulio Favalli, Gian Luca Erre, Roberto Gorla, Mauro Galeazzi, Rosario Foti, Fabrizio Cantini, Carlo Salvarani, Ignazio Olivieri, Giovanni Lapadula, Gianfranco Ferraccioli

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Objective Obesity is a mild, long-lasting inflammatory disease and, as such, could increase the inflammatory burden of rheumatoid arthritis (RA). The study aim was to determine whether obesity represents a risk factor for a poor remission rate in RA patients requiring anti-tumor necrosis factor α (anti-TNFα) therapy for progressive and active disease despite treatment with methotrexate or other disease-modifying antirheumatic drugs. Methods Patients were identified from 15 outpatient clinics of university hospitals and hospitals in Italy taking part in the Gruppo Italiano di Studio sulle Early Arthritis network. Disease Activity Score in 28 joints (DAS28), body mass index (BMI; categorized as 30 kg/m2), acute-phase reactants, IgM rheumatoid factor, and anti-cyclic citrullinated peptide antibody values were collected. DAS28 remission was defined as a score of 30 kg/m2 was recorded in 66 (10.3%) of 641 RA patients. After 12 months of anti-TNFα treatment, a DAS28 of 2, and in 32.9% of the patients with a BMI of 2 (P = 0.01). The lowest percentage of remission, which was statistically significant versus adalimumab and etanercept (P = 0.003), was observed with infliximab. Conclusion Obesity represents a risk factor for a poor remission rate in patients with longstanding RA treated with anti-TNFα agents. A personalized treatment plan might be a possible solution.

Original languageEnglish
Pages (from-to)94-100
Number of pages7
JournalArthritis Care and Research
Volume65
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Precision Medicine
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Obesity
Joints
Antirheumatic Agents
Acute-Phase Proteins
Rheumatoid Factor
Therapeutics
Ambulatory Care Facilities
Methotrexate
Italy
Arthritis
Immunoglobulin M
Body Mass Index
Antibodies

ASJC Scopus subject areas

  • Rheumatology

Cite this

Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis : An approach to a personalized medicine. / Gremese, Elisa; Carletto, Antonio; Padovan, Melissa; Atzeni, Fabiola; Raffeiner, Bernd; Giardina, Anna Rita; Favalli, Ennio Giulio; Erre, Gian Luca; Gorla, Roberto; Galeazzi, Mauro; Foti, Rosario; Cantini, Fabrizio; Salvarani, Carlo; Olivieri, Ignazio; Lapadula, Giovanni; Ferraccioli, Gianfranco.

In: Arthritis Care and Research, Vol. 65, No. 1, 01.2013, p. 94-100.

Research output: Contribution to journalArticle

Gremese, E, Carletto, A, Padovan, M, Atzeni, F, Raffeiner, B, Giardina, AR, Favalli, EG, Erre, GL, Gorla, R, Galeazzi, M, Foti, R, Cantini, F, Salvarani, C, Olivieri, I, Lapadula, G & Ferraccioli, G 2013, 'Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine', Arthritis Care and Research, vol. 65, no. 1, pp. 94-100. https://doi.org/10.1002/acr.21768
Gremese, Elisa ; Carletto, Antonio ; Padovan, Melissa ; Atzeni, Fabiola ; Raffeiner, Bernd ; Giardina, Anna Rita ; Favalli, Ennio Giulio ; Erre, Gian Luca ; Gorla, Roberto ; Galeazzi, Mauro ; Foti, Rosario ; Cantini, Fabrizio ; Salvarani, Carlo ; Olivieri, Ignazio ; Lapadula, Giovanni ; Ferraccioli, Gianfranco. / Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis : An approach to a personalized medicine. In: Arthritis Care and Research. 2013 ; Vol. 65, No. 1. pp. 94-100.
@article{7b8e21ff81434d14bed82003051457c8,
title = "Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine",
abstract = "Objective Obesity is a mild, long-lasting inflammatory disease and, as such, could increase the inflammatory burden of rheumatoid arthritis (RA). The study aim was to determine whether obesity represents a risk factor for a poor remission rate in RA patients requiring anti-tumor necrosis factor α (anti-TNFα) therapy for progressive and active disease despite treatment with methotrexate or other disease-modifying antirheumatic drugs. Methods Patients were identified from 15 outpatient clinics of university hospitals and hospitals in Italy taking part in the Gruppo Italiano di Studio sulle Early Arthritis network. Disease Activity Score in 28 joints (DAS28), body mass index (BMI; categorized as 30 kg/m2), acute-phase reactants, IgM rheumatoid factor, and anti-cyclic citrullinated peptide antibody values were collected. DAS28 remission was defined as a score of 30 kg/m2 was recorded in 66 (10.3{\%}) of 641 RA patients. After 12 months of anti-TNFα treatment, a DAS28 of 2, and in 32.9{\%} of the patients with a BMI of 2 (P = 0.01). The lowest percentage of remission, which was statistically significant versus adalimumab and etanercept (P = 0.003), was observed with infliximab. Conclusion Obesity represents a risk factor for a poor remission rate in patients with longstanding RA treated with anti-TNFα agents. A personalized treatment plan might be a possible solution.",
author = "Elisa Gremese and Antonio Carletto and Melissa Padovan and Fabiola Atzeni and Bernd Raffeiner and Giardina, {Anna Rita} and Favalli, {Ennio Giulio} and Erre, {Gian Luca} and Roberto Gorla and Mauro Galeazzi and Rosario Foti and Fabrizio Cantini and Carlo Salvarani and Ignazio Olivieri and Giovanni Lapadula and Gianfranco Ferraccioli",
year = "2013",
month = "1",
doi = "10.1002/acr.21768",
language = "English",
volume = "65",
pages = "94--100",
journal = "Arthritis care and research : the official journal of the Arthritis Health Professions Association",
issn = "0893-7524",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis

T2 - An approach to a personalized medicine

AU - Gremese, Elisa

AU - Carletto, Antonio

AU - Padovan, Melissa

AU - Atzeni, Fabiola

AU - Raffeiner, Bernd

AU - Giardina, Anna Rita

AU - Favalli, Ennio Giulio

AU - Erre, Gian Luca

AU - Gorla, Roberto

AU - Galeazzi, Mauro

AU - Foti, Rosario

AU - Cantini, Fabrizio

AU - Salvarani, Carlo

AU - Olivieri, Ignazio

AU - Lapadula, Giovanni

AU - Ferraccioli, Gianfranco

PY - 2013/1

Y1 - 2013/1

N2 - Objective Obesity is a mild, long-lasting inflammatory disease and, as such, could increase the inflammatory burden of rheumatoid arthritis (RA). The study aim was to determine whether obesity represents a risk factor for a poor remission rate in RA patients requiring anti-tumor necrosis factor α (anti-TNFα) therapy for progressive and active disease despite treatment with methotrexate or other disease-modifying antirheumatic drugs. Methods Patients were identified from 15 outpatient clinics of university hospitals and hospitals in Italy taking part in the Gruppo Italiano di Studio sulle Early Arthritis network. Disease Activity Score in 28 joints (DAS28), body mass index (BMI; categorized as 30 kg/m2), acute-phase reactants, IgM rheumatoid factor, and anti-cyclic citrullinated peptide antibody values were collected. DAS28 remission was defined as a score of 30 kg/m2 was recorded in 66 (10.3%) of 641 RA patients. After 12 months of anti-TNFα treatment, a DAS28 of 2, and in 32.9% of the patients with a BMI of 2 (P = 0.01). The lowest percentage of remission, which was statistically significant versus adalimumab and etanercept (P = 0.003), was observed with infliximab. Conclusion Obesity represents a risk factor for a poor remission rate in patients with longstanding RA treated with anti-TNFα agents. A personalized treatment plan might be a possible solution.

AB - Objective Obesity is a mild, long-lasting inflammatory disease and, as such, could increase the inflammatory burden of rheumatoid arthritis (RA). The study aim was to determine whether obesity represents a risk factor for a poor remission rate in RA patients requiring anti-tumor necrosis factor α (anti-TNFα) therapy for progressive and active disease despite treatment with methotrexate or other disease-modifying antirheumatic drugs. Methods Patients were identified from 15 outpatient clinics of university hospitals and hospitals in Italy taking part in the Gruppo Italiano di Studio sulle Early Arthritis network. Disease Activity Score in 28 joints (DAS28), body mass index (BMI; categorized as 30 kg/m2), acute-phase reactants, IgM rheumatoid factor, and anti-cyclic citrullinated peptide antibody values were collected. DAS28 remission was defined as a score of 30 kg/m2 was recorded in 66 (10.3%) of 641 RA patients. After 12 months of anti-TNFα treatment, a DAS28 of 2, and in 32.9% of the patients with a BMI of 2 (P = 0.01). The lowest percentage of remission, which was statistically significant versus adalimumab and etanercept (P = 0.003), was observed with infliximab. Conclusion Obesity represents a risk factor for a poor remission rate in patients with longstanding RA treated with anti-TNFα agents. A personalized treatment plan might be a possible solution.

UR - http://www.scopus.com/inward/record.url?scp=84871821443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871821443&partnerID=8YFLogxK

U2 - 10.1002/acr.21768

DO - 10.1002/acr.21768

M3 - Article

VL - 65

SP - 94

EP - 100

JO - Arthritis care and research : the official journal of the Arthritis Health Professions Association

JF - Arthritis care and research : the official journal of the Arthritis Health Professions Association

SN - 0893-7524

IS - 1

ER -